Q3 Revenue Slips to $7.6M, Net Loss Widens to $11.4M as Cash Falls to $1.0M
BSEM sits 30% above its 52-week low of $1 on elevated volume (2.1× avg).
Summary
BioStem posted Q3 2026 revenue of $7.6 million, down from $7.9 million in Q2 and $10.5 million a year ago, while the GAAP net loss widened to $11.4 million ($0.64 per share) from $9.0 million in Q2. Gross margin compressed to 56% from 61% sequentially and 88.5% a year ago, driven by higher pricing under the BioTissue supply agreement after the initial discount period expired. Cash fell to $1.0 million from $7.0 million at June 30, with $8.8 million burned in operations during the quarter — a thin cushion against a $10.0 million Clearance Payment owed to BioTissue that remains unpaid and is being renegotiated. The offsetting positives: hospital revenue grew sequentially to $6.8 million, customers buying two or more product lines rose 14% from Q2, and full-year 2026 revenue guidance was raised to $28-29 million from $26-29 million. Management is finalizing a cost plan it says will cut $10-12 million of annualized cash operating expenses starting Q1 2027, and in-house Neox/Clarix production is targeted for the first half of 2027. Top-line VLU study results are due at the Innovations in Wound Healing meeting in early December.
At the time of this announcement, BSEM was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3M. The 52-week trading range was $1.00 to $8.40. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.